News About: Pharm. Industry
Merging process of Pfizer and Allergan starts
Pfizer and Allergan will become one.
Recognized as the most interesting deal of the last year, the merger of the two companies has been visualized.
According to the industry concerned on the 22nd, the Pfizer’s hea...
Multinational pharmaceuticals’ distribution policies as ‘Selection and Concentration’
Multinational pharmaceutical companies have started to change their marketing policies to ‘Selection and Concentration.’
According to the industry concerned on the 22nd, Boehringer Ingelheim recently opened cooperati...
About 10 companies cannot even pay back interests with profitsAmong listed pharmaceutical companies, it was observed there were 10 companies which cannot even pay for interests of their loans with earnings made by their business activities...
|
Listed pharmaceutical companies spent KRW 500 billion into advertising
It was observed listed pharmaceutical companies exceeded KRW 50 million in spending expenses into advertising last year.
This is because a number of pharmaceutical companies have actively worked on invigoration of no...
Will rebate investigation team investigate Japanese companies too?
While a large multinational pharmaceutical company, Novartis, has become a target for prosecution investigation, the industry has paid attention to which will be the next target of the rebate investigation team.
As ...
3-year GMP investment of KRW 1 trillion
Domestic pharmaceutical companies were observed to put approximately KRW 1 trillion into establishing GMP facilities for 3 years from this year to 2018.
Thus, the pharmaceutical industry has paid attention to expansi...
“If others are obeying CP, the effect of illegal rebates get double or triple”
“There are some companies criticizing (such as illegal rebates) in the front, while having rebate activities in the back. Is it because the effect of illegal rebates become even larger while other competing companies ...
‘Domestic rare disease treatments’ grew as leading products
Pricey rare disease treatments have grown as leading products of domestic pharmaceutical companies.
Since they are expensive as essential drugs despite the small number of patients needing them, their sales have been...
Handok-Teva acquires commercialization approval for Symbicort genericA competitor against an AstraZeneca’s asthma and COPD drug recording annual KRW 10 billion sales, ‘Symbicort Turbuhaler(budesonide/formoterol),’ emerged.
As Handok-Teve succee...
|
One of three listed pharmaceutical companies spent over 40% of sales into sales management expenses
One of three listed pharmaceutical companies were aggregated to spend 40% of their sales on sales management expenses. In order to raise profits, pharmaceutical companies have been working on reducing the fees, but it...
